



This report is prepared for the Warsaw Stock Exchange SA within the framework of the Analytical Coverage Support Program 3.0.

Daily 22.VIII.2022

Company	LT fundamental recommendation	12M EFV (PLN)	ST market-relative bias	Analyst
<b>BioMaxima</b>	<b>Not rated</b>	<b>37.3</b>	<b>Not rated</b>	Sylwia Jaśkiewicz, CFA Mikołaj Stępień

**Event: Buyback update**

The Company informed that it purchased 125,500 shares (2.9% of the share capital) for PLN 3.6 million which implies an average price per share in the pending buyback at c. PLN 28.61. BioMaxima has spent already 72% of the amount earmarked for the buyback (PLN 5 million).

**Expected impact:** *Neutral.*

---

*The report is not a recommendation within the meaning of Commission Delegated Regulation (EU) 2016/958 of 9 March 2016 supplementing Regulation (EU) No 596/2014 of the European Parliament and of the Council with regard to regulatory technical standards for technical arrangements for objective presentation of investment recommendations or other information recommending or suggesting an investment strategy and for disclosure of particular interests or indications of conflicts of interest.*